Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.
- Firsekibart (Jin Beixin)
- Suvemcitug (Enzheshu)
Q3 2025 saw various acquisitions, collaborations, and licensing agreements of up to US$8 billion. Investment into antibody drug startups has focused on artificial intelligence platforms and antibody bispecific formats.
Gain exclusive insights into current trends such as:
- 📣 2 novel antibody drugs approved for the first time in Q3
- 💸 Top 10 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8B
- 🤖 Current research into designing antibodies from scratch (de novo)
- 🔬 Immune cell engagers as a bispecific antibody format
- 💊 A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q4 2025